OTCMKTS:POLXF - Polydex Pharmaceuticals Stock Price, News, & Analysis

0.00 (0.00 %)
(As of 07/19/2019 04:00 PM ET)
Today's Range
Now: $1.05
50-Day Range
MA: $1.07
52-Week Range
Now: $1.05
Average Volume1,961 shs
Market Capitalization$3.59 million
P/E Ratio10.50
Dividend YieldN/A
Polydex Pharmaceuticals Limited, through its subsidiaries, manufactures bulk pharmaceutical intermediates for the veterinary pharmaceutical industry worldwide. It also develops, manufactures, and markets biotechnology-based products for the human pharmaceutical market. The company primarily offers dextran and derivative products, including Iron Dextran, a derivative of dextran that is injected into pigs at birth as a treatment for anemia; and dextran sulphate, a specialty chemical derivative of dextran used in biotechnology applications and the pharmaceutical industry. It also provides ferric hydroxide and hydrogenated dextran to Sparhawk Laboratories Inc. In addition, the company develops Ushercell, a high molecular weight cellulose sulphate for topical vaginal use primarily in the prevention and transmission of AIDS and other sexually transmitted diseases, as well as unplanned pregnancies; and Usherdex 4, a low molecular weight dextran product for the treatment of cystic fibrosis, a genetic disease. Polydex Pharmaceuticals Limited sells its iron dextran primarily to independent distributors and wholesalers primarily in Europe, the Far East, South America, and Canada; and Dextran Sulphate to independent distributors or companies in the United States and Europe for analytical applications. The company was formerly known as Polydex Chemicals Limited and changed its name to Polydex Pharmaceuticals Limited in March 1984. Polydex Pharmaceuticals Limited was founded in 1966 and is based in Toronto, Canada.

Industry, Sector and Symbol

Industry Industrial inorganic chemicals



Sales & Book Value

Annual Sales$4.94 million
Cash Flow$0.1498 per share
Book Value$1.69 per share


Net Income$230,000.00


Market Cap$3.59 million
Next Earnings Date9/18/2019 (Estimated)
OptionableNot Optionable

Receive POLXF News and Ratings via Email

Sign-up to receive the latest news and ratings for POLXF and its competitors with MarketBeat's FREE daily newsletter.

Polydex Pharmaceuticals (OTCMKTS:POLXF) Frequently Asked Questions

What is Polydex Pharmaceuticals' stock symbol?

Polydex Pharmaceuticals trades on the OTCMKTS under the ticker symbol "POLXF."

How were Polydex Pharmaceuticals' earnings last quarter?

Polydex Pharmaceuticals Ltd (OTCMKTS:POLXF) issued its earnings results on Wednesday, May, 1st. The company reported $0.01 earnings per share (EPS) for the quarter. The company had revenue of $1.04 million for the quarter. Polydex Pharmaceuticals had a return on equity of 5.69% and a net margin of 6.89%. View Polydex Pharmaceuticals' Earnings History.

When is Polydex Pharmaceuticals' next earnings date?

Polydex Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, September 18th 2019. View Earnings Estimates for Polydex Pharmaceuticals.

Has Polydex Pharmaceuticals been receiving favorable news coverage?

News coverage about POLXF stock has trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Polydex Pharmaceuticals earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Polydex Pharmaceuticals.

Who are some of Polydex Pharmaceuticals' key competitors?

What other stocks do shareholders of Polydex Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Polydex Pharmaceuticals investors own include Global Energy Metals (GEMC), Editas Medicine (EDIT), La Jolla Pharmaceutical (LJPC), Eli Lilly And Co (LLY), Select Medical (SEM), Credit Suisse AM Inc Fund (CIK), CaNickel Mining (CML), Bayer (BAYN), MediGene (MDG1) and Lanxess (LXS).

Who are Polydex Pharmaceuticals' key executives?

Polydex Pharmaceuticals' management team includes the folowing people:
  • Mr. George G. Usher, Chairman, CEO & Pres (Age 60)
  • Ms. Sharon L. Wardlaw, COO, Treasurer & Sec. (Age 66)
  • Mr. David Jamestee, Chief Financial Officer

How do I buy shares of Polydex Pharmaceuticals?

Shares of POLXF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Polydex Pharmaceuticals' stock price today?

One share of POLXF stock can currently be purchased for approximately $1.05.

How big of a company is Polydex Pharmaceuticals?

Polydex Pharmaceuticals has a market capitalization of $3.59 million and generates $4.94 million in revenue each year. Polydex Pharmaceuticals employs 23 workers across the globe.View Additional Information About Polydex Pharmaceuticals.

What is Polydex Pharmaceuticals' official website?

The official website for Polydex Pharmaceuticals is http://www.polydex.com/.

How can I contact Polydex Pharmaceuticals?

Polydex Pharmaceuticals' mailing address is 421 COMSTOCK ROAD, TORONTO A6, M1L 2H5. The company can be reached via phone at 416-755-2231 or via email at [email protected]

MarketBeat Community Rating for Polydex Pharmaceuticals (OTCMKTS POLXF)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  67 (Vote Outperform)
Underperform Votes:  50 (Vote Underperform)
Total Votes:  117
MarketBeat's community ratings are surveys of what our community members think about Polydex Pharmaceuticals and other stocks. Vote "Outperform" if you believe POLXF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe POLXF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel